EFPIA - NEWSLETTER

EFPIA Newsletter 24 September 2020

Supporting the development of rare disease R&D in Europe

"In normal times, rare diseases don’t always receive a high level of attention from the medical community. But, during the COVID-19 pandemic, it can seem that rare disease is even further down the agenda", says Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

"An incredible amount of attention has understandably been dedicated to COVID-19. This has had an impact on those living with other health conditions, including rare diseases. Throughout the crisis, pharma companies have worked tirelessly to ensure the continuity of clinical trials in extremely challenging circumstances."

Statements

24 September 2020 Publication of a new report “Benefits beyond the EU Falsified Medicines Directive - The hospital...

The EU Falsified Medicines Directive supports hospitals to realise significant benefits

22 September 2020 Vaccines Europe statement on the Hearing on "How to secure access to COVID-19 vaccines for...

#WeWontRest until there is a COVID-19 vaccine for everyone

Blogs

24 September 2020 #FHaware2020 – A multi-stakeholder collaboration to resolve the burden of FH

Every year, on September 24th, the international Familial Hypercholesterolemia (FH) community celebrates FH Awareness...

21 September 2020 21 September is World Alzheimer's Day (Guest blog)

#WeWontRest in our mission to bring new hope to patients affected by devastating diseases with a high unmet medical...

21 September 2020 Recent data has given both us and the Alzheimer’s community some hope in an environment where...

#WeWontRest until we can change the course of the disease for people living with Alzheimer’s disease and give them and...

21 September 2020 Alzheimer’s disease: The importance of early diagnosis

#WeWontRest until we succeed in making meaningful improvements to the lives of people impacted by Alzheimer’s disease,...

21 September 2020 One Cold and Wet Night late in January 2020

We know times are very difficult and challenging for Head & Neck Cancer patients and their Caregivers. And these patients...

Videos

Alzheimer’s Disease – The Time to Act is Now

We are at a turning point in our fight against Alzheimer's disease. Long-awaited new therapies are on the horizon. #WeWontRest until patients and society are able to fully realise the benefits of these new therapies https://bit.ly/2ZE53Mq

A new wave of innovation is bringing hope to patients living with Alzheimer’s

“We see a new wave of innovation bringing hope to patients living with Alzheimer’s. #WeWontRest as an industry in combatting this challenge” David Jefferys, Global Senior Vice President Global Regulatory, Government Relations, Corporate Affairs and Patient Safety at Eisai EMEA, and Chair of the EFPIA Alzheimer's Disease platform.

#WeWontRest until innovative treatments can hold the Alzheimer's disease in its tracks

"With new Alzheimer's treatments on the horizon, it will be possible to protect the patient’s cognitive abilities. But the clinical journey needs to adapt to these breakthroughs. #WeWontRest until innovative treatments can hold the Alzheimer's disease in its tracks" - Johanna Friedl-Naderer, President Europe and Canada, Biogen.

Every Day Counts: Improving time to patient access to innovative oncology therapies in Europe

For cancer patients, Every Day Counts… but significant differences exist in patient access to innovative oncology therapies in Europe. Accelerating time to patient access will be critical to beat cancer in Europe.

Can you make enough COVID-19 vaccine to supply the whole world?

Finding a COVID-19 vaccine is one of the biggest challenges we’ve ever faced.
Developing and manufacturing a vaccine usually takes many years.
But with COVID-19, the world needs solutions quickly. So we’re working at an unprecedented rate, whilst ensuring we never compromise when it comes to safety.

Are we doing the best we can for the 60 million Europeans living with diabetes?

Diabetes is Europe’s silent health pandemic, but is the diagnosis, treatment and management of diabetes getting the focus it deserves?
Patients endure the relentless task of managing their disease, acutely aware that it develops and changes over time, with connected diseases emerging possibly later in life, such as amputations, heart attacks or strokes.

Upcoming EFPIA events

28 SEP 2020

Neurological diseases: Lessons learnt from COVID and the future of neuroscience Virtual event

EFNA, EFPIA and EBC are delighted to invite you to join this virtual event.

Learn more →

05 OCT 2020

What delays access to medicines? Virtual event

Join our next debate about the root causes of unavailability of medicines and delays for patients across the EU #QuestionsInspireSolutions...

Learn more →

#WeWontRest until Alzheimer's patients see a brighter future

Alzheimer’s Disease Health System Readiness – The Time to Act is Now 21 September 2020 (Publications)

We are at a turning point in our fight against dementia and Alzheimer’s disease. Long-awaited new therapies are on the...

What we are reading

MEPs call for transparency in race for COVID vaccine amid rising vaccine hesitancy 22 September 2020 (Euractiv)

How close is a coronavirus vaccine? | Free to read 23 September 2020 (Financial Times)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶